Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide

References

• Buckner JC, Brown PD, O’Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007; 82:1271 - 86; http://dx.doi.org/10.4065/82.10.1271; PMID: 17908533
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459 - 66; http://dx.doi.org/10.1016/S1470-2045(09)70025-7; PMID: 19269895
   PubMed Web of Science ®Google Scholar
• van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 2003; 13:92 - 100; http://dx.doi.org/10.1016/S0962-8924(02)00039-9; PMID: 12559760
   PubMed Web of Science ®Google Scholar
• García-Cardeña G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997; 272:25437 - 40; http://dx.doi.org/10.1074/jbc.272.41.25437; PMID: 9325253
   PubMed Web of Science ®Google Scholar
• Navarro A, Anand-Apte B, Parat MO. A role for caveolae in cell migration. FASEB J 2004; 18:1801 - 11; http://dx.doi.org/10.1096/fj.04-2516rev; PMID: 15576483
   PubMed Web of Science ®Google Scholar
• Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8:185 - 94; http://dx.doi.org/10.1038/nrm2122; PMID: 17318224
   PubMed Web of Science ®Google Scholar
• Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002; 54:431 - 67; http://dx.doi.org/10.1124/pr.54.3.431; PMID: 12223531
   PubMed Web of Science ®Google Scholar
• Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, et al. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 2000; 275:21203 - 9; http://dx.doi.org/10.1074/jbc.M000321200; PMID: 10747899
   PubMed Web of Science ®Google Scholar
• Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol 2008; 48:359 - 91; http://dx.doi.org/10.1146/annurev.pharmtox.48.121506.124841; PMID: 17914930
   PubMed Web of Science ®Google Scholar
• Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288:C494 - 506; http://dx.doi.org/10.1152/ajpcell.00458.2004; PMID: 15692148
   PubMed Web of Science ®Google Scholar
• Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008; 27:715 - 35; http://dx.doi.org/10.1007/s10555-008-9160-9; PMID: 18506396
   PubMed Web of Science ®Google Scholar
• Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol 2007; 31:760 - 9; http://dx.doi.org/10.1097/01.pas.0000213433.14740.5d; PMID: 17460461
   PubMed Web of Science ®Google Scholar
• Barresi V, Buttarelli FR, Vitarelli EE, Arcella A, Antonelli M, Giangaspero F. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status. Hum Pathol 2009; 40:1738 - 46; http://dx.doi.org/10.1016/j.humpath.2009.04.026; PMID: 19716156
   PubMed Web of Science ®Google Scholar
• Senetta R, Trevisan E, Rudà R, Maldi E, Molinaro L, Lefranc F, et al. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol 2009; 68:425 - 31; http://dx.doi.org/10.1097/NEN.0b013e31819ed0b7; PMID: 19287309
   PubMed Web of Science ®Google Scholar
• Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, Dontenwill M. Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta 2009; 1793:354 - 67; http://dx.doi.org/10.1016/j.bbamcr.2008.09.019; PMID: 18992284
   PubMed Web of Science ®Google Scholar
• Cosset EC, Godet J, Entz-Werlé N, Guérin E, Guenot D, Froelich S, et al. Involvement of the TGFβ pathway in the regulation of α5 β1 integrins by caveolin-1 in human glioblastoma. Int J Cancer 2012; 131:601 - 11; http://dx.doi.org/10.1002/ijc.26415; PMID: 21901744
   PubMed Web of Science ®Google Scholar
• Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004; 23:6967 - 79; http://dx.doi.org/10.1038/sj.onc.1207911; PMID: 15273741
   PubMed Web of Science ®Google Scholar
• Forget MA, Desrosiers RR, Del M, Moumdjian R, Shedid D, Berthelet F, et al. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin Exp Metastasis 2002; 19:9 - 15; http://dx.doi.org/10.1023/A:1013884426692; PMID: 11918088
   PubMed Web of Science ®Google Scholar
• Cameron PL, Liu C, Smart DK, Hantus ST, Fick JR, Cameron RS. Caveolin-1 expression is maintained in rat and human astroglioma cell lines. Glia 2002; 37:275 - 90; http://dx.doi.org/10.1002/glia.10036; PMID: 11857686
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998; 428:205 - 11; http://dx.doi.org/10.1016/S0014-5793(98)00470-0; PMID: 9654135
   PubMed Web of Science ®Google Scholar
• Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 2003; 284:C457 - 74; PMID: 12388077
   PubMed Web of Science ®Google Scholar
• Han F, Gu D, Chen Q, Zhu H. Caveolin-1 acts as a tumor suppressor by down-regulating epidermal growth factor receptor-mitogen-activated protein kinase signaling pathway in pancreatic carcinoma cell lines. Pancreas 2009; 38:766 - 74; http://dx.doi.org/10.1097/MPA.0b013e3181b2bd11; PMID: 19893453
   PubMed Web of Science ®Google Scholar
• Schmitz M, Zerr I, Althaus HH. Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades. Cell Mol Neurobiol 2011; 31:991 - 7; http://dx.doi.org/10.1007/s10571-011-9694-1; PMID: 21523467
   PubMed Web of Science ®Google Scholar
• Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176:2626 - 37; http://dx.doi.org/10.2353/ajpath.2010.091117; PMID: 20395445
   PubMed Web of Science ®Google Scholar
• Feng S, Wang Y, Wang X, Wang Z, Cui Y, Liu J, et al. Caveolin-1 gene silencing promotes the activation of PI3K/AKT dependent on Eralpha36 and the transformation of MCF10ACE. Science China. Life Sci 2010; 53:598 - 605; http://dx.doi.org/10.1007/s11427-010-0100-x
   Web of Science ®Google Scholar
• Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278 - 93; http://dx.doi.org/10.1016/j.ajpath.2012.03.017; PMID: 22698676
   PubMed Web of Science ®Google Scholar
• Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10:319 - 31; http://dx.doi.org/10.1038/nrc2818; PMID: 20414201
   PubMed Web of Science ®Google Scholar
• Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 2007; 113:295 - 302; http://dx.doi.org/10.1007/s00401-006-0186-1; PMID: 17235514
   PubMed Web of Science ®Google Scholar
• Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010; 28:1930 - 9; http://dx.doi.org/10.1002/stem.521; PMID: 20857497
   PubMed Web of Science ®Google Scholar
• Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65:1181 - 8; http://dx.doi.org/10.1097/01.jnen.0000248549.14962.b2; PMID: 17146292
   PubMed Web of Science ®Google Scholar
• Lopez-Gines C, Gil-Benso R, Benito R, Mata M, Pereda J, Sastre J, et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 2008; 28:507 - 15; http://dx.doi.org/10.1111/j.1440-1789.2008.00911.x; PMID: 18410277
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170:1445 - 53; http://dx.doi.org/10.2353/ajpath.2007.070011; PMID: 17456751
   PubMed Web of Science ®Google Scholar
• Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97 - 117; http://dx.doi.org/10.1146/annurev.pathol.1.110304.100043; PMID: 18039109
   PubMed Web of Science ®Google Scholar
• Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630 - 46; http://dx.doi.org/10.1074/jbc.M409214200; PMID: 15355971
   PubMed Web of Science ®Google Scholar
• Kim HN, Chung HS. Caveolin-1 inhibits membrane-type 1 matrix metalloproteinase activity. BMB Rep 2008; 41:858 - 62; http://dx.doi.org/10.5483/BMBRep.2008.41.12.858; PMID: 19123976
   PubMed Web of Science ®Google Scholar
• Han F, Zhu HG. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res 2010; 159:443 - 50; http://dx.doi.org/10.1016/j.jss.2009.03.079; PMID: 20031158
   PubMed Web of Science ®Google Scholar
• Reunanen N, Westermarck J, Häkkinen L, Holmström TH, Elo I, Eriksson JE, et al. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998; 273:5137 - 45; http://dx.doi.org/10.1074/jbc.273.9.5137; PMID: 9478967
   PubMed Web of Science ®Google Scholar
• Kim S, Lee Y, Lee DH, Kim Y, Cho KH, Chung JH. Basal and UV-induced MMP-1 expression are inhibited by p53 in human dermal fibroblasts. Exp Dermatol 2008; 17:939 - 45; http://dx.doi.org/10.1111/j.1600-0625.2008.00729.x; PMID: 18557930
   PubMed Web of Science ®Google Scholar
• Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999; 274:11535 - 40; http://dx.doi.org/10.1074/jbc.274.17.11535; PMID: 10206959
   PubMed Web of Science ®Google Scholar
• Shetty P, Velusamy T, Bhandary YP, Shetty RS, Liu MC, Shetty S. Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover. Am J Respir Cell Mol Biol 2008; 39:364 - 72; http://dx.doi.org/10.1165/rcmb.2007-0406OC; PMID: 18390474
   PubMed Web of Science ®Google Scholar
• Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol 2010; 31:643 - 50; http://dx.doi.org/10.1007/s13277-010-0081-1; PMID: 20820979
   PubMed Web of Science ®Google Scholar
• Yang X, Xiong H, Guan ZZ, Okai I, Ye D, Song Y, et al. Higher expression of Caveolin-1 inhibits human small cell lung cancer (SCLC) apoptosis in vitro. Cancer Invest 2012; 30:453 - 62; http://dx.doi.org/10.3109/07357907.2012.675384; PMID: 22545709
   PubMed Web of Science ®Google Scholar
• Zhang M, Lee SJ, An C, Xu JF, Joshi B, Nabi IR, et al. Caveolin-1 mediates Fas-BID signaling in hyperoxia-induced apoptosis. Free Radic Biol Med 2011; 50:1252 - 62; http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.031; PMID: 21382479
   PubMed Web of Science ®Google Scholar
• Torres VA, Tapia JC, Rodríguez DA, Párraga M, Lisboa P, Montoya M, et al. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 2006; 119:1812 - 23; http://dx.doi.org/10.1242/jcs.02894; PMID: 16608879
   PubMed Web of Science ®Google Scholar
• Zhang M, Lin L, Lee SJ, Mo L, Cao J, Ifedigbo E, et al. Deletion of caveolin-1 protects hyperoxia-induced apoptosis via survivin-mediated pathways. Am J Physiol Lung Cell Mol Physiol 2009; 297:L945 - 53; http://dx.doi.org/10.1152/ajplung.00081.2009; PMID: 19767411
   PubMed Web of Science ®Google Scholar
• Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res 2007; 67:2849 - 56; http://dx.doi.org/10.1158/0008-5472.CAN-06-4082; PMID: 17363608
   PubMed Web of Science ®Google Scholar
• Bruyère C, Abeloos L, Lamoral-Theys D, Senetta R, Mathieu V, Le Mercier M, et al. Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol 2011; 4:92 - 100; PMID: 21461172
   PubMed Web of Science ®Google Scholar
• Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007; 13:1663 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-06-2854; PMID: 17363519
   PubMed Web of Science ®Google Scholar
• Jodoin J, Demeule M, Fenart L, Cecchelli R, Farmer S, Linton KJ, et al. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem 2003; 87:1010 - 23; http://dx.doi.org/10.1046/j.1471-4159.2003.02081.x; PMID: 14622130
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhu J, Zhao L, Luo Q, Jin X. Expression and clinical significance of multidrug resistance proteins in brain tumors. Journal of experimental & clinical cancer research. CR (East Lansing, Mich) 2010; 29:122
   Google Scholar
• Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther 2008; 7:1212 - 25; http://dx.doi.org/10.4161/cbt.7.8.6220; PMID: 18458534
   PubMed Web of Science ®Google Scholar
• Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008; 59:105 - 10; http://dx.doi.org/10.1016/j.lungcan.2007.07.024; PMID: 17850918
   PubMed Web of Science ®Google Scholar
• Nakatani K, Wada T, Nakamura M, Uzawa K, Tanzawa H, Fujita S. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131:445 - 52; http://dx.doi.org/10.1007/s00432-004-0662-8; PMID: 15856296
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545 - 50; http://dx.doi.org/10.1073/pnas.0506580102; PMID: 16199517
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al, The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 2000; 25:25 - 9; http://dx.doi.org/10.1038/75556; PMID: 10802651
   PubMed Web of Science ®Google Scholar